• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Heroin and Healthcare: Patient Characteristics and Healthcare Prior to Overdose

The American Journal of Managed CareJuly 2019
Volume 25
Issue 7

An analysis of administrative claims showed increasing rates of heroin overdose among an insured population and opportunities for interventions during healthcare encounters before overdose.


Objectives: To estimate heroin overdose trends among insured individuals and characterize patients and healthcare utilization preceding overdose to inform scale-up of effective prevention and treatment.

Study Design: Retrospective descriptive analysis.

Methods: We analyzed 2010 to 2014 IBM MarketScan Databases and calculated annual heroin overdose rates. For a subset of patients, we describe their comorbidities, where they accessed health services, and select prescription histories prior to their first heroin overdose.

Results: Heroin overdose rates were much lower, but increased faster, among the commercially insured compared with Medicaid enrollees from 2010 to 2014 (270.0% vs 94.3%). By 2012, rates among the commercially insured aged 15 to 24 years reached the overall rates in the Medicaid population. All patients had healthcare encounters in the 6 months prior to their first heroin overdose; two-thirds of commercially insured patients had outpatient visits, whereas two-thirds of Medicaid patients had emergency department visits. One month prior to overdose, 24.5% of Medicaid and 8.6% of commercially insured patients had opioid prescriptions. Fewer Medicaid patients had buprenorphine prescriptions (17.8% vs 27.3%) despite similar rates of known substance-related disorders. A higher proportion of Medicaid patients had non—substance-related comorbidities.

Conclusions: Heroin overdose rates were persistently higher among the Medicaid population than the commercially insured, with the exception of those aged 15 to 24 years. Our findings on healthcare utilization, comorbidities, and where individuals access services could inform interventions at the point of care prior to a first heroin overdose. Outpatient settings are of particular importance for the growing cohort of young, commercially insured patients with opioid use disorders.

Am J Manag Care. 2019;25(7):341-347Takeaway Points

Healthcare utilization patterns among insured patients who experience heroin overdose highlight opportunities for interventions before the first overdose, noting differences in patient characteristics and healthcare access points by insurance type.

  • Medicaid and commercial insurance pay for approximately half of heroin overdoses, and nearly all insured patients access healthcare services in the 6 months prior to overdose.
  • Outpatient interventions are important for the emerging cohort of young, commercially insured patients with opioid use disorder.
  • Many insured patients who experience heroin overdose have multiple comorbidities, emphasizing the importance of coordinated care, including mental health care, judicious opioid and benzodiazepine prescribing, medication-assisted treatment, provision of naloxone, and prevention of infectious disease transmission.

America’s opioid epidemic continues to grow. The negative health outcomes and healthcare costs associated with the epidemic are well documented,1 with opioid overdose fatalities making up the most acute and reliable measure. In 2014, the CDC reported the highest number of opioid overdose fatalities (28,647) during any previous year on record,2 only to report that this unprecedented number was surpassed with 47,600 opioid overdose deaths by 2017.3

Although the rising number of annual opioid overdose deaths indicates that the opioid epidemic has not yet peaked, the relative contribution of different drug types to the epidemic is changing. In 2015, the CDC reported that the heroin-involved overdose mortality rate was increasing more than overdose deaths involving commonly prescribed opioids (20.6% vs 2.5%).4 As heroin deaths approach the number of prescription opioid deaths, another challenge has emerged from illicitly manufactured fentanyl (IMF).5

The dynamic nature of the opioid overdose epidemic poses continuous challenges to prevention efforts.6 Despite the problem of polysubstance use among heroin users,7 demographic changes in opioid use patterns are also well documented. Younger patients have higher prevalence of heroin use disorders,8 and national reports identify that the largest increases in percentage of individuals with heroin use disorder from 2010 to 2014 are among those aged 18 to 25 years.9 National death data similarly show high heroin overdose rates among younger age groups.3,4 Heroin is frequently adulterated with IMF, and deaths involving synthetic opioids, such as fentanyl, are also highest among younger age groups.3-5

These studies of recent trends in heroin use and mortality are critically important for identifying at-risk groups. However, they do not provide essential information on the underlying patterns in healthcare utilization preceding an overdose or prior prescription opioid use—an important concern given the association between opioid use disorders involving prescription opioids and heroin.7 For this study, we aimed to characterize trends in heroin overdoses treated in healthcare settings for an insured population and to describe healthcare encounters before the overdose, including diagnoses and use of prescription opioids, benzodiazepines, and buprenorphine. Patients treated for heroin overdose in healthcare settings include those who survive the overdose, as well as those for whom the overdose was fatal. We used longitudinal patient-level and payer-specific data to explore these characteristics and identify whether opportunities for preoverdose interventions exist, given that interventions are frequently initiated when an overdose occurs but there may be opportunities to intervene further upstream. These aspects provide insight into the diverging trajectory of the heroin epidemic, including patients’ risk profiles beyond substance use disorders, and may contribute to a more effective prevention strategy.


Data Source

Data for Medicaid and commercially insured enrollees were analyzed separately for 2010 to 2014. We analyzed administrative claims data from IBM MarketScan Research Databases, which are derived from a convenience sample of commercially insured and Medicaid enrollees. Approximately half of the US population is covered by employer-sponsored commercial health plans,10 and the IBM MarketScan Commercial Databases capture data on more than a quarter of these individuals annually from every state in the United States. Approximately 20% of the US population is covered by Medicaid.11 The IBM MarketScan Multi-State Medicaid Databases are derived from 10 to 13 unidentified geographically dispersed states from each of the 4 Census regions, capturing both fee-for-service and managed care data. The numbers of enrollees in our sample for each study year are provided in Table 1. The IBM MarketScan Databases encompass the full continuum of healthcare, including inpatient, outpatient, and emergency department (ED) services, as well as prescriptions dispensed through retail pharmacies.

Of note, Medicaid and commercial health plans cover approximately half of all ED visits and admissions in the United States for heroin overdose (data not shown). Our analysis focuses on those who overdose on heroin and are insured, and we acknowledge that there may be differences between them and those who are uninsured. Although insured individuals who overdose on heroin are not representative of all who overdose on heroin, they are most likely to be affected by reforms in clinical practice and insurance oversight.


IBM MarketScan provides access to data on enrollees who have prescription drug coverage. All analyses were restricted to enrollees aged 15 to 64 years, as there are few heroin overdoses in younger adolescents and children, and the number of enrollees 65 years or older drops off considerably as they transition to Medicare. When calculating annual rates, we included only individuals continuously enrolled throughout a given calendar year. For 2014 Medicaid data, we included only individuals who were continuously enrolled in both 2013 and 2014. This kept our sample consistent by reducing the impact of a large increase in MarketScan Medicaid enrollees in 2014 due in part to Medicaid expansion under the Affordable Care Act.

Measures and Analyses

Overdose rates. Within each calendar year, we identified enrollees with at least 1 inpatient, outpatient, or ED claim with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis of 965.01 (poisoning by heroin) or E850.0 (accidental poisoning by heroin). We then stratified our study population by gender and age categories to calculate heroin overdose rates by demographic characteristics. Distinct from the diagnostic codes for heroin overdose, we also calculated opioid (other than heroin) overdose rates (eAppendix [available at ajmc.com]) for each year to compare with heroin overdose trends. In 2017, Green et al reported that ICD-9-CM codes for opioid-related poisoning had a very high predictive value, suggesting that they can be used to monitor overdose rates.12

Healthcare utilization, prescriptions, and diagnoses prior to overdose. We next conducted additional analyses on a subset of patients experiencing heroin overdose. We examined diagnoses, healthcare utilization, and select controlled substance prescriptions among patients experiencing heroin overdose who had 18 months of continuous enrollment prior to their first heroin overdose in the study period. Eighteen months provided a retrospective period with no heroin overdose, such that the index heroin overdose event we examined was regarded as the “first heroin overdose” for our study purposes. We had access to data from 2009 but not 2008, so we excluded patients with a heroin overdose occurring in the first 6 months of 2010.

We then assessed the proportion of patients with at least 1 ED visit, inpatient admission, or outpatient visit in the 6 months prior to the impending overdose to highlight opportunities for screening, intervention, or referral during such encounters. Encounters in the 14 days prior to the overdose were not considered to avoid capturing claims that may have been related to the first heroin overdose and to focus on missed opportunities that would have allowed a reasonable amount of time for intervention prior to the index event. We also determined the proportion of patients filling a prescription for buprenorphine indicated for the treatment of opioid use disorder anytime up to 3 days before the overdose. We next determined the proportion of patients with prescriptions for opioids in the 6 months, 3 months, and 1 month prior to the overdose, and repeated this for benzodiazepines. Lastly, we identified common diagnoses in the 6 months prior to the heroin overdose using categories from the Healthcare Cost and Utilization Project Clinical Classifications Software for ICD-9-CM.13 Diagnoses included those received in the course of inpatient admissions or during outpatient or ED visits.


Overdose Rates

Heroin overdose rates were lower than opioid (other than heroin) overdose rates but increased over time. We observed much higher heroin overdose rates among the Medicaid population compared with the commercially insured population, but rates increased faster among the commercially insured from 2010 to 2014 (Table 1). Heroin overdose rates increased 270.0% among the commercially insured—from 1.9 to 7.1 per 100,000 enrollees—during the study period. Among the Medicaid population, these rates increased 94.3% during the same time period—from 15.7 to 30.5 per 100,000 enrollees. In contrast, opioid (other than heroin) overdose rates remained fairly stable, although much higher than heroin overdose rates.

Heroin overdose rates were consistently higher among male than female enrollees, irrespective of health insurance type. In 2014, the rates of heroin overdose among male and female enrollees were 10.5 and 4.1 per 100,000 commercial enrollees, respectively, and 34.9 and 28.0 per 100,000 Medicaid enrollees, respectively. The highest heroin overdose rates among the commercially insured were in the youngest age group—those aged 15 to 24 years (30.3 per 100,000 in 2014)—whereas among the Medicaid population, this age group had the lowest rates (14.0 per 100,000 in 2014). In 2012, heroin overdose rates among the commercially insured aged 15 to 24 years were similar to the overall rates of heroin overdose in the Medicaid population. Among the commercially insured, heroin overdose rates declined as age category increased, whereas rates remained steady among Medicaid enrollees aged 35 to 64 years.

Healthcare Utilization, Prescriptions, and Diagnoses Prior to Overdose

Nearly all enrollees with heroin overdose had at least 1 healthcare encounter in the 6 months prior to their first overdose, including approximately 1 in 4 having an inpatient admission (Table 213). A higher proportion of commercially insured (64.7%) than Medicaid (36.6%) patients had outpatient visits, whereas the opposite was true for ED visits (35.5% vs 62.1%). A consistently higher proportion of Medicaid patients were prescribed opioids prior to their heroin overdose. For instance, within 1 month of the overdose, 24.5% of Medicaid patients and 8.6% of commercially insured patients had prescriptions for opioids, which is a nearly 3-fold difference. Additionally, a higher proportion of Medicaid patients were prescribed benzodiazepines. Specifically, 29.0% of Medicaid and 14.5% of commercially insured patients received benzodiazepine prescriptions within 1 month of the overdose. More enrollees on Medicaid (14.5% vs 3.9%) were also prescribed both benzodiazepines and opioids within 1 month of overdose. Prescriptions for buprenorphine indicated for the treatment of opioid use disorder were prescribed less frequently for Medicaid patients than commercially insured patients (17.8% vs 27.3%) preceding the overdose.

Table 213 lists the categories of diagnoses received by patients in the 6 months prior to their heroin overdose. Similar proportions of both Medicaid and commercially insured populations were diagnosed with substance-related disorders other than alcohol and tobacco (approximately 49%) (see eAppendix for codes for opioid overdose and substance-related disorders) and with alcohol-related disorders specifically (approximately 14%). However, for all other diagnoses, the proportion receiving the diagnosis was higher among the Medicaid than commercially insured patients. Notably, there were approximately 3-fold higher proportions of Medicaid patients than commercially insured patients with diagnoses of nonspecific chest pain, other nervous system disorders, and hepatitis (all forms of viral hepatitis and chronic hepatitis associated with liver disease and cirrhosis).


We found increasing trends in heroin overdose rates that reflect previously reported increases in heroin use and heroin-related overdose deaths.7,14 During the study period of 2010 to 2014, opioid (other than heroin) overdose rates remained stable, whereas heroin overdose rates increased steadily among most demographic groups year to year; however, we acknowledge that these increases were relative to initially small heroin overdose rates. Our findings that men, young adults, and Medicaid enrollees had the highest rates of heroin overdose are consistent with prior research.3,7-9 Our inclusion of nonfatal overdoses and demographic stratifications by payer type provide additional insight into the trajectory of the heroin epidemic. Among the commercially insured population, the highest heroin overdose rates were among those aged 15 to 24 years. During 2012 to 2014, this is the only age group among the commercially insured whose rates were similar to those of their Medicaid counterparts and the overall rates among the Medicaid population. This may represent an emerging cohort of commercially insured individuals with high prevalence of heroin use. In comparison, the same age group with Medicaid insurance had the lowest heroin overdose rates among all Medicaid age groups in every year. All other Medicaid age groups (ages 25-64 years) had consistently high heroin overdose rates, signaling persistent substance use disorder prevalence.15,16 Although rates of heroin overdose are currently lower among the commercially insured, their numbers may account for a substantial burden from heroin overdose given that more than half of the US population is covered by employer-sponsored commercial health plans.10

Healthcare utilization patterns prior to heroin overdoses indicate that nearly all enrollees had at least 1 healthcare encounter (all diagnoses) in the 6 months prior to their first overdose; the majority of commercially insured patients (64.7%) received healthcare through outpatient visits, whereas most Medicaid patients (62.1%) accessed the ED. This is consistent with what we know about insurance type and healthcare access in general.17 Healthcare utilization patterns prior to heroin overdoses confirm that these high-risk insured patients are not “lost to follow-up” or absent from healthcare settings. This emphasizes the importance of the healthcare system’s role in preventing overdoses by offering brief interventions, coordinating medical and mental health services, and linking patients to appropriate care, such as substance use disorder treatment. Differences in patient healthcare utilization patterns based on payer type have implications for prevention efforts aimed at those at risk for heroin overdose. This knowledge allows for the development of targeted evidence-based strategies specific to the healthcare settings where these populations are most likely to access care. Although EDs are frequent sites of interventions related to substance use disorders, outpatient settings could be explored to better target young, commercially insured patients at risk for overdose.

Prescribing patterns prior to overdose show that opioid prescribing was higher among the Medicaid population, which could be related to high rates of comorbidities known to cause pain. A greater proportion of Medicaid patients had diagnoses of mood, anxiety, or nervous system disorders; connective tissue disease; joint disorders; back problems; lower respiratory diseases; and hepatitis. High prevalence of comorbidities in our population is consistent with Medicaid populations in general, but nonetheless underscores the importance of screening to ensure that all underlying conditions are appropriately treated. Given that the highest heroin overdose rate in the commercially insured population was among those aged 15 to 24 years, the finding of a relatively lower proportion of commercially insured with opioid prescriptions could be due to adolescents and young adults being more likely than other age groups to obtain prescription opioids from a friend or relative.18 Another explanation could relate to individuals now more frequently reporting heroin as their opioid of initiation.19 Additionally, a higher proportion of the Medicaid population received both opioid and benzodiazepine prescriptions prior to heroin overdose. We found higher benzodiazepine prescribing than opioid prescribing, which is the opposite of what is true for opioid and benzodiazepine prescribing prevalence in the general population20,21 and likely reflects more mental health conditions in our study population.

The association between poorer overall health and higher opioid utilization emphasizes the need for clinicians to coordinate care and adopt evidence-based prescribing practices. Judicious opioid prescribing, in accordance with the CDC Guideline for Prescribing Opioids for Chronic Pain,22 would be warranted among our high-risk study group, many of whom had documented histories of substance use disorders. In addition to monitoring illicit drug use, clinicians can use prescription drug monitoring data to check if patients have overlapping opioid and/or benzodiazepine prescriptions. The concurrent use of opioids and benzodiazepines should be avoided per the FDA’s new warnings.22-25

Although nearly half of all patients who overdosed on heroin in this study were previously diagnosed with substance-related disorders, relatively few had prescriptions for buprenorphine, 1 of the 3 medications used in medication-assisted treatment (MAT) for opioid use disorder. These low proportions, especially among Medicaid patients, signal opportunities for improving access to this therapy and potentially preventing overdose. Research has shown that MAT can be effective in the treatment of opioid use disorder and can reduce healthcare utilization.26

Screening and treatment for hepatitis C and HIV is of particular importance for all patients using heroin. Many individuals who report heroin use inject the drug,27 which carries considerable risk for the transmission of bloodborne diseases through needle sharing. In accordance with recommendations from the CDC,28 those who inject drugs should be tested for HIV and hepatitis and vaccinated against viral hepatitis B if not immune. Access to comprehensive syringe services programs is also crucial for individuals who use heroin to mitigate risk of overdose and of bloodborne pathogen transmission. Although a nearly 3-fold greater proportion of the Medicaid population had diagnosed hepatitis (16.8% vs 6.1%), many hepatitis B and C infections remain undiagnosed in the United States. The emerging cohort of young, commercially insured patients with high heroin overdose rates warrants further investigation to determine whether they have hepatitis or other infectious disease rates more similar to the Medicaid population.


There are limitations to consider with regard to our results. First, the study may have yielded different results if the analyses were not restricted to the continuously enrolled population. For example, “churning” is common among Medicaid enrollees, whereby individuals fluctuate between states of eligibility and ineligibility, resulting in sporadic coverage.29 It is known that continuously enrolled patients are more likely to have chronic conditions.30-32 A second limitation is the potential effect resulting from Medicaid expansion under the Affordable Care Act. In 2013, rates of substance use disorders among currently uninsured Medicaid-eligible individuals were found to be slightly higher than the rates among current Medicaid enrollees.33 Because we excluded newly eligible Medicaid enrollees, the rates of heroin overdose in our study are likely conservative. A third limitation is that variability in coding practices means that the opioid overdoses we identified could potentially include some heroin overdoses. However, Green et al found high positive predictive values for opioid and heroin overdose codes.12 Fourth, results are not nationally representative and should be interpreted with caution. Finally, due to the nature of claims data, heroin overdoses that did not involve transport to a medical facility, including fatal overdoses, may not have been captured.


Medicaid and private insurance pay for nearly half of heroin overdoses in the United States. Healthcare encounters for heroin overdose increased significantly from 2010 to 2014 for these groups. Rates among Medicaid enrollees were higher, yet rates increased faster among the commercially insured. Healthcare utilization patterns among insured patients who overdose on heroin suggest that opportunities exist for interventions at the point of care prior to the first overdose. We noted differences in where patients accessed care by insurance coverage type, which can inform targeted and tailored prevention efforts. Outpatient settings are of particular importance for the emerging cohort of young, commercially insured patients aged 15 to 24 years with opioid use disorder. Moreover, many patients in our study had multiple comorbidities in addition to known substance use disorders. This emphasizes the importance of coordinated care for all underlying conditions, judicious prescribing practices in accordance with the CDC’s guideline, referral to or induction on MAT, provision of naloxone, and screening and referral to treatment and prevention resources for viral hepatitis and HIV.Author Affiliations: Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC (MKB, KZ), Atlanta, GA; Booz Allen Hamilton (LB), Atlanta, GA; Behavioral and Urban Health Program, RTI International (JEZ), Atlanta, GA.

Source of Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC.

Author Disclosures: The authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Authorship Information: Concept and design (MKB, JEZ, KZ); acquisition of data (MKB); analysis and interpretation of data (MKB, LB, JEZ, KZ); drafting of the manuscript (MKB, LB, JEZ, KZ); critical revision of the manuscript for important intellectual content (MKB, LB, JEZ, KZ); statistical analysis (MKB); administrative, technical, or logistic support (MKB, LB); and supervision (MKB).

Address Correspondence to: Michele K. Bohm, MPH, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC, 4770 Buford Hwy NE, Mailstop F62, Atlanta, GA 30341-3717. Email: mbohm@cdc.gov.REFERENCES

1. Luo F, Florence C. State-level lifetime medical and work-loss costs of fatal injuries—United States, 2014 [erratum in MMWR Morb Mortal Wkly Rep. 2017;66(7):196. doi: 10.15585/mmwr.mm6607a5]. MMWR Morb Mortal Wkly Rep. 2017;66(1):1-11. doi: 10.15585/mmwr.mm6601a1.

2. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382. doi: 10.15585/mmwr.mm6450a3.

3. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019;67(51-52):1419-1427. doi: 10.15585/mmwr.mm675152e1.

4. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349-358. doi: 10.15585/mmwr.mm6712a1.

5. Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths—27 states, 2013-2014. MMWR Morb Mortal Wkly Rep. 2016;65(33):837-843. doi: 10.15585/mmwr.mm6533a2.

6. Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373(18):1789-1790. doi: 10.1056/NEJMc1505541.

7. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719-725.

8. Martins SS, Sarvet A, Santaella-Tenorio J, Saha T, Grant BF, Hasin DS. Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions [erratum in JAMA Psychiatry. 2017;74(10):1079. doi: 10.1001/jamapsychiatry.2017.2725]. JAMA Psychiatry. 2017;74(5):445-455. doi: 10.1001/jamapsychiatry.2017.0113.

9. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration website. samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm. Published September 2015. Accessed July 15, 2017.

10. Barnett JC, Vornovitsky MS. Health Insurance Coverage in the United States, 2015. Washington, DC: US Government Printing Office; 2016. census.gov/content/dam/Census/library/publications/2016/demo/p60-257.pdf. Accessed July 2017.

11. Medicaid and CHIP enrollment as a percentage of the U.S. population, 2017. Medicaid and CHIP Payment and Access Commission website. macpac.gov/publication/medicaid-and-chip-enrollment-as-a-percentage-of-the-u-s-population. Accessed June 12, 2019.

12. Green CA, Perrin NA, Janoff SL, Campbell CI, Chilcoat HD, Coplan PM. Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. Pharmacoepidemiol Drug Saf. 2017;26(5):509-517. doi: 10.1002/pds.4157.

13. Clinical Classifications Software (CCS) for ICD-9-CM. Agency for Healthcare Research and Quality website. hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Published 2016. Accessed December 15, 2016.

14. Hedegaard H, Chen LH, Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief. 2015;(190):1-8.

15. Braden JB, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD. Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain. 2008;9(11):1026-1035. doi: 10.1016/j.jpain.2008.06.002.

16. Coolen P, Best S, Lima A, Sabel H, Paulozzi L. Overdose deaths involving prescription opioids among Medicaid enrollees—Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58(42):1171-1175.

17. Revisiting emergency department use in Medicaid. Medicaid and CHIP Payment and Access Commission website. macpac.gov/wp-content/uploads/2015/01/MACFacts-EDuse_2014-07.pdf. Published July 2014. Accessed August 15, 2017.

18. Lipari RN, Hughes A. How people obtain the prescription pain relievers they misuse. Substance Abuse and Mental Health Services Administration website. samhsa.gov/data/sites/default/files/report_2686/ShortReport-2686.html. Published January 12, 2017. Accessed October 15, 2017.

19. Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017;74:63-66. doi: 10.1016/j.addbeh.2017.05.030.

20. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142. doi: 10.1001/jamapsychiatry.2014.1763.

21. Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM; CDC. Controlled substance prescribing patterns—Prescription Behavior Surveillance System, eight states, 2013. MMWR Surveill Summ. 2015;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.

22. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624-1645. doi: 10.1001/jama.2016.1464.

23. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use [news release]. Silver Spring, MD: FDA; August 31, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm. Accessed July 15, 2017.

24. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012;13(1):87-95. doi: 10.1111/j.1526-4637.2011.01260.x.

25. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. doi: 10.1136/bmj.j760.

26. Mohlman MK, Tanzman B, Finison K, Pinette M, Jones C. Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont. J Subst Abuse Treat. 2016;67:9-14. doi: 10.1016/j.jsat.2016.05.002.

27. Novak SP, Kral AH. Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States. J Addict Dis. 2011;30(3):248-257. doi: 10.1080/10550887.2011.581989.

28. CDC. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012;61(RR-5):1-40.

29. Swartz K, Short PF, Graefe DR, Uberoi N. Reducing Medicaid churning: extending eligibility for twelve months or to end of calendar year is most effective. Health Aff (Millwood). 2015;34(7):1180-1187. doi: 10.1377/hlthaff.2014.1204.

30. Amendah DD, Grosse SD, Bertrand J. Medical expenditures of children in the United States with fetal alcohol syndrome. Neurotoxicol Teratol. 2011;33(2):322-324. doi: 10.1016/j.ntt.2010.10.008.

31. Jensen ET, Cook SF, Allen JK, et al. Enrollment factors and bias of disease prevalence estimates in administrative claims data. Ann Epidemiol. 2015;25(7):519-525.e2. doi: 10.1016/j.annepidem.2015.03.008.

32. Peacock G, Amendah D, Ouyang L, Grosse SD. Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions. J Dev Behav Pediatr. 2012;33(1):2-8. doi: 10.1097/DBP.0b013e31823969de.

33. Busch SH, Meara E, Huskamp HA, Barry CL. Characteristics of adults with substance use disorders expected to be eligible for Medicaid under the ACA. Psychiatr Serv. 2013;64(6):520-526. doi: 10.1176/appi.ps.201200011.

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.